Portal de Periódicos da CAPES

Clinical and in vitro Response to 13-cis-Retinoic Acid in Interferon-alpha Resistant Renal Cell Carcinoma

1997; Mary Ann Liebert, Inc.; Volume: 12; Issue: 3 Linguagem: Inglês

10.1089/cbr.1997.12.143

1557-8852

Jan Buer, Michael Probst, Stefan Duensing, H Köditz, Anke Franzke, Iris Dallmann, Arnold Ganser, Jens Atzpodien,

Lymphoma Diagnosis and Treatment

Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients. The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive. In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha. Among 21 patients treated there were one complete and four partial remissions (objective response rate, 24%; median response duration 8+ months). Preliminary evidence suggests that 13cRA acid may reverse IFN-alpha resistance in renal cell carcinoma.